| This week's sponsor is LabVantage. | | | |
Today's Rundown After a string of failures, Axovant CEO Hung resigns, along with a host of others Roche bispecific antibody tops Lucentis in diabetic eye disease Roivant expands into metabolic diseases with $650M Poxel diabetes pact After last year’s cuts, Ardelyx loses CSO Caldwell as he becomes CEO at a startup Atlas’ I-O startup Surface names CEO with IPO experience Bristol-Myers taps Sirenas for 'global microbiome' drug discovery Making inroads toward eliminating latent HIV reservoirs Special Report—Top 10 most productive workforces in biopharma Featured Story | | | Monday, February 12, 2018 After a very brief and tumultuous tenure at the startup with big hopes and backing, former Medivation chief David Hung, M.D., has resigned as CEO of Axovant. |
|
|
Top Stories Monday, February 12, 2018 Roche has reported midstage data with its double-headed antibody RG7716 in diabetic macular edema, which suggests it could be a threat to current blockbuster VEGF drugs used for the disease. Monday, February 12, 2018 Roivant Sciences has struck a $650 million deal to acquire near-global rights to Poxel’s phase 3-ready Type 2 diabetes drug imeglimin. The deal ends Poxel’s long wait for a partner capable of shouldering the burden of a late-phase diabetes program and starts Roivant’s expansion into metabolic diseases. Monday, February 12, 2018 Ardelyx has faced a tough few years with trial setbacks and axing staffers. Today, it announced chief scientific officer Jeremy Caldwell, Ph.D., is heading for the exit, with no replacement yet lined up. Monday, February 12, 2018 Surface Oncology has named Jeff Goater as its CEO. Goater landed the post with a résumé that lists a starring role in Voyager Therapeutics’ IPO and a decade in investment banking among its highlights. Monday, February 12, 2018 Bristol-Myers Squibb and Sirenas inked a research collaboration to identify drug candidates for a number of “challenging therapeutic targets.” Monday, February 12, 2018 As successful as antiretroviral therapy has been in suppressing HIV, the virus that causes AIDS, many patients are left with latent viral “reservoirs” that hide in the body and can resurge at any time. Two recent advances are focused on using new technology to combat these HIV reservoirs. Monday, February 12, 2018 The math is simple, but managing a company isn’t. That’s the message we gleaned in analyzing productivity at major pharmas and biotech companies. Resources Presented by: Box and USDM Life Sciences Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process. Sponsored by: RBC Wealth Management Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public Presented by: Patheon Download Patheon’s whitepaper to discover two main areas where a drug developer can face significant obstacles during biologics development and how by evaluating these capabilities, it can answer the critical question of whether its in-house strategy is ready for these uncertainties. Presented by: SDC and Stiris Research What do you do when timelines are missed, data is dirty, and everyone is pointing fingers? From study delays to quality issues, sponsors can find their studies at risk with no clear solution. Watch this webinar to learn how to prevent, identify, and implement a successful clinical trial rescue. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA PEGS: The Essential Protein Engineering Summit April 30-May 4 | Boston, MA Healthcare Internet of Things February 13-14, 2018 | Moscone South Convention Center | San Francisco, CA Partnering for Growth 2018 March 20th | 7:30 am-6 pm
March 21st | 7:30 am-1:15 pm | 